Sensor and other revenues (96% of total revenues ... Total assets amounted to $6.35 billion, down sequentially from $6.79 billion. DexCom reiterated its outlook for 2024 revenues.

DexCom, Inc. DXCM reported third-quarter ... The broader S&P 500 index has moved up 21.6% in the same period. Sensor and other revenues (96% of total revenues) increased 9% on a year-over-year ...

DexCom, Inc. DXCM is scheduled to release third ... Currently, the Zacks Consensus Estimate for revenues is pegged at $991.6 million, indicating growth of 1.7% from the year-ago quarter’s ...

Revenue declined 1.6% year-over-year from $713.6 million in ... Every study in these AID systems has been done with the DexCom sensor. So there aren't any head-to-head studies.

CNW/ - Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. This approval represents an important step ...

DexCom, Inc. DXCM reported third ... The broader S&P 500 index has moved up 21.6% in the same period. Image Source: Zacks Investment Research Sensor and other revenues (96% of total revenues ...

Dexcom stock closed in the red on Friday after the diabetes devices player beat third-quarter expectations and kept its ...

Medtronic (NYSE: MDT) Q2 2025 Earnings Call Nov 19, 2024, 8:00 a.m. ET ...

Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.

Medtronic plc's Q2 earnings show moderate growth, highlighting potential for shareholder value through strategic initiatives. Click for my MDT earnings update.